Ketamine Linked to Brain Shifts in Older Adults' Depression

Ketamine May Reshape Brain Activity Patterns Tied to Depression in Older Adults

A report from Medical Xpress, published September 12, 2026, describes research linking ketamine treatment to shifting brain activity patterns associated with depression improvement in older adults. Ketamine is a dissociative anesthetic studied since the early 2000s for its rapid antidepressant effects, particularly in people with treatment-resistant depression, a form of major depressive disorder that has not improved after at least two standard antidepressant trials. The available summary of this research does not specify the brain regions monitored, the imaging or recording method used, the ketamine dose or route of administration, or the number of participants studied, so this analysis focuses on what the finding is likely to mean for readers rather than restating specifics the source has not provided.

What is reported is directionally consistent with earlier ketamine research. Several published studies using EEG, a method that records electrical activity across the scalp, and fMRI, functional magnetic resonance imaging that tracks blood flow changes tied to brain activity, have found that ketamine alters connectivity in mood-regulating circuits, including the default mode network, within hours of dosing. Whether this new research used the same tools is not stated in the available material, and readers should treat the underlying brain mechanism as a subject of continuing research rather than a settled fact.

Older adults are a comparatively understudied group in ketamine research. Age-related changes in liver function, kidney clearance, and body composition can affect how any drug, including ketamine, is absorbed, distributed, and cleared. A study that specifically tracks brain activity changes in this age group is notable partly because interest in oral ketamine has grown through telehealth-based programs that prescribe compounded tablets or lozenges for at-home use under remote clinical supervision, and older patients are increasingly part of that population.

What This Means for Oral Ketamine Tablet Users

Oral ketamine tablets pass through the liver before reaching the bloodstream, a process called first-pass metabolism that reduces bioavailability to roughly 20 to 25 percent. That compares with close to 100 percent for intravenous infusion, an estimated 25 to 50 percent for sublingual troches held under the tongue, and variable but generally higher absorption for intramuscular injection. Intranasal esketamine, sold under the brand name Spravato and approved by the FDA in 2019 for treatment-resistant depression, follows a different absorption path through the nasal mucosa. Age-related changes in liver enzyme activity can shift how much active ketamine and norketamine, its main metabolite, actually reach the brain after a swallowed tablet, which matters directly for the population this new research focuses on. If brain activity changes linked to depression improvement turn out to be dose-dependent, a route with lower and more variable bioavailability, like an oral tablet, could produce a different or slower response curve than the infusion-based studies that make up much of the existing evidence base.

For readers using or considering oral ketamine tablets, the practical takeaway is to treat absorption variability as a known limitation to manage rather than a flaw to fear. Taking tablets consistently, following the prescribing clinic's instructions on timing and food intake, and reporting mood and side effect patterns at each follow-up visit gives a prescriber the information needed to judge whether a dose or route adjustment is warranted. Because older adults are more likely to take other medications processed through the same liver pathways, bringing a current medication list to every ketamine visit remains one of the simplest safety steps available. Clinicians treating older patients often start at lower doses and monitor blood pressure and cognitive effects more closely, given age-related sensitivity to dissociative and sedative effects.

What Remains Unclear

The available source description does not name the imaging method, sample size, ketamine dose, administration route, or the journal where the underlying study appeared, and Ketamine Tablet has not independently reviewed the primary research paper. Readers who want to evaluate the evidence directly should look for the peer-reviewed journal article once it is indexed, since early press coverage sometimes describes findings before full methodological details are public. If future research confirms that specific brain activity patterns predict who responds to ketamine, that could eventually help guide dose or route selection, including for oral tablet regimens, though no such biomarker test exists in current clinical practice as of 2026. Until a primary source is available, this finding is worth watching as an early signal rather than a change to established guidance for oral ketamine use in older adults.